<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 1, 1997
OSI PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-15190 13-3159796
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
106 Charles Lindbergh Blvd., Uniondale, NY 11553
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (516) 222-0023
Oncogene Science, Inc.
(Former name or former address, if changed since last report)
<PAGE> 2
ITEM 5. OTHER EVENTS
Effective October 1, 1997, Oncogene Science, Inc. ("OSI") changed its name
to OSI Pharmaceuticals, Inc. This change was effected under Delaware law in
connection with the merger into OSI of one of its wholly owned subsidiaries. In
addition, effective October 1, 1997, OSI's Nasdaq National Market symbol was
changed to "OSIP."
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
--------------------------------------------
Robert L. Van Nostrand,
Vice President, Chief Financial Officer,
Secretary and Treasurer
Dated: October 3, 1997
